DETAILS, FICTION AND ABBV-744 IN ACUTE MYELOID LEUKEMIA (AML)

In Section C, participants will get ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will get treatment until disorder progression or even the members are unable to tolerate the study drugs.then promote H3K27Ac at this area. Chromatin hyperacetylation could enhance the accessibility in the